• Wiley Online Library will be disrupted on 18 May from 10:00-12:00 BST (05:00-07:00 EDT) for essential maintenance
You have full text access to this OnlineOpen article

Amine precursor therapy: Manipulation of brain amine activity with precursor amino acid

  1. TERUO NAKAJIMA MD*

Article first published online: 28 JUN 2008

DOI: 10.1111/j.1440-1819.1997.tb03197.x

Issue

Psychiatry and Clinical Neurosciences

Psychiatry and Clinical Neurosciences

Volume 51, Issue 5, pages 267–274, October 1997

Additional Information

How to Cite

NAKAJIMA, T. (1997), Amine precursor therapy: Manipulation of brain amine activity with precursor amino acid. Psychiatry and Clinical Neurosciences, 51: 267–274. doi: 10.1111/j.1440-1819.1997.tb03197.x

Author Information

  1. Department of Sociology, Bukkyo University, Kyoto, Japan

* MD. Bukkyo University, 96 Kita-hananobo-cho, Murasakino. Kita-ku, Kyoto 603, Japan.

Publication History

  1. Issue published online: 28 JUN 2008
  2. Article first published online: 28 JUN 2008
  3. Received 6 May 1997; accepted 19 May 1997.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (725K)

REFERENCES

  • 1
    Sano I. “Precursor Therapy” with active amines — Treatment of depression by 5-HTP (L-5-hydroxytryptopan). Folia Psychiat. Neurol. Japan. 1971; 73: 809–813 (in Japanese).
  • 2
    Sano I., Taniguchi K. “Precursor Therapy” with active amines: Treatment of Parkinson's disease by 5-HTP (L-5-hydroxytrytophan). Folia Psychiat. Neurol. Japan. 1971; 73: 835–839 (in Japanese).
  • 3
    Sano I. Biochemistry of extrapyramidal motor system. Shinkeikenkyu no Shinpo 1960; 5: 42–48 (in Japanese).
  • 4
    Ehringer H. Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-hydroxytyamin) in Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochschr. 1960; 38: 1236–1240 (in German).
  • 5
    Barbeau A. Proceedings of VII International Congress of Neurology, Rome. Sosieta Grafica Romana, Rome 1960; 2: 925.
  • 6
    Birkmayer WZ. Hornykiewicz O. Der L-3,4-Dioxyphenylanine (=DOPA)-Effect bei der Parkinson-Akinese. Wien. Klin. Wochschr. 1961; 45: 787–788 (in German).
  • 7
    Cotzias GC, Von Woert MH, Sciffer LM. Aromatic amino acids and modification of Parkinsonism. N. Engl. J. Med. 1967; 276: 374–378.
  • 8
    Yahr MD, Duvoisin RC, Schcar MJ, Barrett RE, Hoehn MM. Treatment of Parkinsonism with levodopa. Arch. Neurol. 1969; 21: 343–354.
  • 9
    Everett GM, Toman JPE. Mode of action of Rauwolfia alkaloid and motor activity. In: Masserman JH (ed.). Biological Psychiatry, Vol. 1. Grune and Stratton, New York , 1959; 75.
  • 10
    Robin E., Hartman BK. Biochemical theories of mental disorders. In: Eigel GJ, Albers RW, Agranoff BW, Katzman R. (eds). Basic Neurochemistry. 1st edn. Little, Brown & Co., Boston , 1972; 607–644.
  • 11
    Nakajima T., Kudo Y., Kaneko Z. Clinical evaluation of 5-hydroxy-L-tryptophan as an antidepressant drug. Folia Psychiatr. Neurol. Jpn. 1978; 32: 223–230.
  • 12
    Angst J., Woggon B., Schoef J. The treatment of depression with L-hydroxytryptophan versus imipramine. Arch. Psychiatr. Nerven. Kr. 1977; 224: 175–186.
  • 13
    Hornykiewicz O. Die topische Lokalization und des Verhalten von Noradrenalin und Dopamin (3-Hydroxytyramin) in der Substantia nigra der normalen und Parkinson Kranken Menschen. Wien. Klin. Wochschr. 1963; 75: 309–312 (in German).
  • 14
    Johansson B., Roos BE. 5-Hydroxyindoleacetic acid and homovanilic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson's syndrome. Life Sci. 1967; 6: 1449–1454.
  • 15
    Poirier LJ. Sourkes TL. Influence of the substantia nigra on the catecholamine content of the striatum. Brain 1965; 88: 181–192.
  • 36
    Goldstein M., Battista AF, Nakatani S. Anagnoste B. The effects of centrally active drugs in monkeys with mesencephalic lesions. Proc. Natl Acad. Sci. 1966; 63: 1114–1116.
  • 17
    Mesa I., Court J., Euengalida S., Papavasilious PS, Cotzias GC. Modification ot chronic manganese poisoning treatment with L-DOPA and 5-hydroxytryptophan. N. Engl. J. Med. 1970; 282: 5–10.
  • 18
    Chase TN. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in Parkinsonism. Neurol. 1970; 20 (Suppl.): S36–S40.
  • 19
    Taniguchi K. Amine precursor therapy. J. Clin. Science 1973; 9: 1313–1320 (in Japanese).
  • 20
    Nakajima T. Biochemistry of Parkinson's disease. Nihonriusho 1976; 43: 2735–2740 (in Japanese).
  • 21
    Jepson JB, Lovenberg W. Zaltzman P. Gates S., Sjoerdsma A., Udenfirend S. Amine metabolism studies in normal and phenylke-tonuric humans by monoamine oxidase inhibitor. Biochem. J. 1960; 74: 5.
  • 22
    Nakajima T., Kakimoto Y. Sano I. Formation of B-phenylethy-lamine in mammalian tissue and its effect on motor activity in the mouse. J. Pharmacol. Exp. Ther. 1976; 143: 319–325.
  • 23
    Sabelli HC, Borison RL. 2–Phenylethylamine and other adrenergic modulators. Adv. Biochem. Psychophannacol. 1976; 15: 69–74.
  • 24
    Fischer E., Heller B. Miro AH. β-Phenylethylamine in human urine. Arzueimittelforsch. 1968; 18: 1486.
  • 25
    Yaryura-Tobias JA. Use of D-phenylalanine in the treatment of depression. In: Phenylethylamine: Biochemical Mechanism and Clinical Aspect. Marcel Dekker. New York , 1979; 489–508.
  • 26
    Fischer E., Heller B. Nachon MN. Spatz H. Therapy of depression by phenylalanine. Arzneimittelforsch. 1975; 25: 132.
  • 27
    Mosmam AD, Inwang EE, Sabelli HC. The influence of psychotropic drugs on the levels of endogenous 2–phenylethylamine in rat brain. Biol. Psychiatry 1974; 8: 227–237.
  • 28
    Ipar OJ, Fischer E., Heller B. Nachon MN. Therapia de la depression con D-fenilalanina. Pren. Med. Argent. 1974; 61: 498.
  • 29
    Hashimoto H. Nakajima T., Nishimura T., Kudo Y. Takeda Y., Nakao M., Kanaya H., Honguchi Y. Metabolism of D-phenylalanine and its effects on concentrations of brain monoamines and amino acids in rats: A basic study on the possibility ot clinical use of D-phenylalanine as an antidepressant. Folia Psychiatr. Neurol, Japon. 1983; 37: 137–143.
  • 30
    Mann J., Peselow FD, Snyderman S., Gershon S. D-Phenylalanine in edogenous depression. Am. J. Psychiatry 1980; 137: 1611–1612.
  • 31
    Blasehko H., Burn JH, Langemann H. The formation of noradrena-line from dihydroxyphenylserine. Br. J. Pharmacol. 1950; 5: 431–437.
  • 32
    Schmiterlöw CG. The formation in vivo of noradrenaline from 3,4-dihydroxyphenylserine (noradrenaline carboxylic acid). Br. J. Pharmacol. 1951; 5: 431–437.
  • 33
    Sano I. Hirai M., Matsuoka Y., Nakajima T. 3,4-dihydroxy-phenylserine as the precursor ammo acid of noradrenaline. Bulletin of the Japanese Neurochemical Society 1973; 12: 96–98 (in Japanese).
  • 34
    Pletscher A. Aromatic amino acids as precursor of catecholamines. Proceedings of the Fourth International Meeting of the International Society for Neurochemistry, 2631 August. 1973, Tokyo; 104 (Abstract).
  • 35
    Hirai M., Matsuoka Y., Nakajima T., Sano I. Effect of 3,4-dihydroxyphenylsenne on the concentration of brain noradrenaline and level of growth hormone of rats. Med. J. Osaka Univ. 1975; 26: 51–59.
  • 36
    Porter CC, Torchma ML, Ston CA. (S)-Noradrenaline in the tissues of mice and rats given racemic erythro-3,4-dihydroxy-phenylsenne (DOPS). Life Sci. 1972; 11: 787–797.
  • 37
    Creveling CR, Daly J., Tokuyama T., Witkop B. The combined use of L-methyltyrosme and threo-dihydroxyphenylserine: Selective reduction of dopamine levels in the central system. Biochem. Pharmacol. 1968; 17: 65–70.
  • 38
    Mori T., Nakajima T., Hashimoto H., Noto T., Kato N. Effect of DL-eythro-dihydroxyphenylsenne on the locomotor activity of the mouse. Pharmacol. Biochem. Behav. 1985; 22: 979–983.
  • 39
    Mori M., Hashimoto H., Fukui K. Mori T. Noto T., Nakajima T. Effects of L-erythro-3,4-dihydroxyphenylserine on sleep-wakefulness patterns and concentrations of brain catecholamines and serotonin in rats. Jpn. J. Psychiatr. Neurol. 1987; 41: 301–310.
  • 40
    Van Praag HM. Amine hypothesis of affective disorders. In: Iversen LL, Iversen SD. Snyder SH (eds). Handhook of Psychopharmacology, Vol. 13. Plenum Press. New York-London . 1978; 187–297.
  • 41
    Kety SS. The biogenic amines in the central nervous system: Their possible roles in arousal, emotion and learning. In: Schmitt FO (ed.). The Neurosciences: Second Study Program. Rockefeller University Press. New York , 1970; 324–326.
  • 42
    Liang KC, Juler RG, McGaugh JL. Modulating effects of post-training epinephrine on memory: Involvement of the amygdala noradrnergic system. Brain Res. 1986; 368: 125–133.
  • 43
    Harada H., Noto T., Tsuji M., Taga C., Hashimoto H., Nakajima T. Effects of L-threo- and erythro-3,4–dihydroxyphenylserine on learning performance and concentrations of brain noradrenaline and it metabolites in rats. Pharmacol. Biochem. Behav. 1992; 43: 215–221.
  • 44
    Suzuki T., Tsuge I., Higa S. et al. Catecholamine metabolism in familiar amyloid polyneuropathy. Clin. Genetics 1979; 16: 117–124.
    Direct Link:
  • 45
    Suzuki T., Higa I. Sakoda S. et al. Orthostatic hypotension in familiar amyloid neuropathy: Treatment with DL-threo-3.4-dihydrox-xyphenyserinc. Neurology 1981; 31: 1332–1336.
  • 46
    Birkmayer W., Birkmayer G. Lechner H., Riederer P. DL-threo-DOPS in Parkinson's disease: Effects on orthostatic hypotension and dizzmess. J. Neural Transm. 1983; 58: 305–313.
  • 47
    Nagatsu T., Kato T. Numata Y. et al. Phenylethanolamine N-methyltransterase and other enzymes of catecholamine metabolism in human brain. Clin. Chim. Acta. 1977; 75: 221–232.
  • 48
    Narabayashi H., Kondo T., Hayashi A., Suzuki T. Nagatsu T. 1 -threo-3. 4-Dihydroxyphenykerine treatment for akinesia and freezing of parkinsonism. Proc. Japan Acad. 1981; 57 (Series B); 351–354.
  • 49
    Kondo T. Effects of DL-threo-3, 4-dihydroxyphenylserine on Parkinson's disease and pure akinesia. Clinical Neurol. 1984; 24: 280–288 (in Japanese).
  • 50
    Inagaki N., Yamatodani A., Wada H. Histaminergic neuronal system in the brain: Morphology and functionn. In: Yoshida H. (ed.). Endegenons Neuroactive substances. Chugai-Igakusha. Tokyo . 1989; 279–291 (in Japanese).
  • 51
    Pyman FL. Derivatives of glyoxaline-4(or 5)-carboxylic acid: A new synthesis of histidine. J. Chem. Soc. 1916; 109: 186–202.
  • 52
    Bargar G. Dale HH. Chemical structure and sympathomimetic action of amines. J. Physiol. 1910; 41: 19–59.
  • 53
    Hasegawa T. Studies on the formation of β-hydroxyhistamine and its action on histamine receptor in mammals. J. Kyoto Pref. Univ. Med. 1991; 100: 819–830 (in Japanese).
  • 54
    Kamimura H., Hasegawa T. Nakajima T. Formation of B-hydroxy-histamine from β-hydroxy-histidine in rat organs and characterization of its synthetic enzyme prepared from rat stomach. Biomedical Res. 1989; 10 (Suppl. 8): 241–250.
  • 55
    Yamada M. Watanabe T. Hanno S. Fukui H. Wada H. The effects of protease inhibitors on histidine decarboxylase activities and assay of enzyme in various rat tissues. Biochim. Biophys. Acta. 1980; 615: 458–464.
Get PDF (725K)